Detail akcie Eli Lilly online

Business Summary: Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Eli Lilly And Co revenues increased 26% to $8.77B. Net income increased 67% to $2.24B. Revenues reflect Diabetes-Mounjaro segment increase from $568.4M to $1.81B, Oncology-Verzenio segment increase of 40% to $1.05B, U.S. segment increase of 28% to $5.69B, Europe segment increase of 32% to $1.44B. Net income benefited from Net investment gains on equity securitie increase from $13.7M (expense) to $16M (income).